CD133 as a target for colon cancer

Area of Science:

• Oncology
• Cancer Stem Cell Research

Background:

• Cancer stem cell (CSC) models are advancing translational research and clinical implications in various cancers, including colorectal cancer (CRC).
• Standard therapies often fail due to a small population of cells with stem-like properties (self-renewal, differentiation).
• CSCs are identified by stemness-selective conditions or by markers like CD133, a transmembrane glycoprotein found in tumor-initiating cells.

Purpose of the Study:

• To review current understanding of CD133 as a marker for tumor-initiating cells in colorectal cancer (CRC).
• To highlight the necessity for additional markers to accurately identify the cell population capable of tumor recapitulation in immunocompromised mice.

Main Methods:

• Literature review focusing on CD133 as a colorectal cancer stem cell marker.
• Discussion on the limitations of current identification methods and the need for complementary markers.

Main Results:

• CD133 is a putative marker associated with tumor-initiating cells in colorectal cancer.
• Current markers may not be sufficient for precise identification of the CSC population.

Conclusions:

• Accurate identification and characterization of CSCs are essential for developing innovative therapeutic strategies.
• Overcoming therapeutic evasion by cancer cell clones requires a deeper understanding of CSC biology.